Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

Autor: Glitza Oliva IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. icglitza@mdanderson.org., Ferguson SD; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bassett R Jr; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Foster AP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., John I; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hennegan TD; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rohlfs M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Richard J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Iqbal M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dett T; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lacey C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jackson N; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodgers T; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Phillips S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duncan S; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haydu L; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin R; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fischer GM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McCutcheon IE; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien BJ; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tummala S; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Debnam M; Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guha-Thakurta N; Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carapeto FCL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hudgens CW; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huse JT; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tetzlaff MT; Department of Pathology, The University of California San Francisco, San Francisco, CA, USA., Burton EM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Nature medicine [Nat Med] 2023 Apr; Vol. 29 (4), pp. 898-905. Date of Electronic Publication: 2023 Mar 30.